Table 2

Presence of parameter data for each study in a treatment period

Parameter	Period 1					Period 2		Period 3
Parameter	ETN1	ETN2	IFX1	IFX2	ADA	GOL	CZP	USK1	USK2	SEC1	SEC2	APR
Patient characteristics
Male patients (%)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Age	No	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes
Caucasian patients (%)	Yes	Yes	No	No	Yes	Yes	Yes	No	No	Yes	Yes	Yes
Weight	No	No	No	No	Yes	No	Yes	No	No	Yes	Yes	Yes
Disease characteristics
Duration of PsA	No	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No	Yes
Patients with dactylitis (%)	No	No	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Patients with enthesitis (%)	No	No	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Patients with BSA ≥3% (%)	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Disease activity
SJC	NO	NO	YES	YES	YES	YES	YES	NO	NO	YES	YES	YES
TJC	NO	NO	YES	YES	YES	YES	YES	NO	NO	YES	YES	YES
CRP level	NO	NO	YES	YES	YES	YES	NO	NO	NO	NO	NO	YES
Physician's global assessment of disease activity (VAS)	NO	NO	YES	YES	YES	NO	YES	NO	NO	YES	YES	YES
Patient's global assessment of disease activity (VAS)	NO	NO	YES	YES	YES	NO	YES	NO	NO	YES	YES	YES
Patient's global assessment of pain (VAS)	NO	NO	YES	YES	YES	NO	YES	NO	NO	YES	YES	YES
DAS	NO	NO	YES	NO	NO	YES	NO	NO	NO	YES	YES	YES
PASI	NO	NO	NO	YES	YES	YES	NO	NO	NO	YES	YES	YES
Disease effects
TSS	NO	YES	NO	NO	YES	NO	YES	NO	NO	YES	NO	NO
HAQ-DI score	NO	NO	YES	YES	YES	NO	YES	NO	NO	YES	YES	YES
Prior treatments
Patients with prior anti-TNF therapy (%)	NO	NO	NO	NO	NO	NO	YES	NO	NO	YES	YES	YES
Patients with baseline use of MTX (%)	YES	YES	NO	YES	YES	YES	YES	YES	YES	YES	YES	YES
Patients with baseline use of oral CS (%)	YES	YES	NO	YES	NO	YES	NO	YES	YES	YES	YES	YES
Patients with baseline use of NSAIDs (%)	YES	YES	NO	YES	NO	YES	NO	YES	YES	NO	NO	YES

ADA, adalimumab; APR, apremilast; BSA, body surface area; CRP, C reactive protein; CS, corticosteroid; CZP, certolizumab pegol; DAS, Disease Activity Score; ETN, etanercept; GOL, golimumab; HAQ-DI, Health Assessment Questionnaire Disability Index; IFX, infliximab; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis; SEC, secukinumab; SJC, swollen joint count;; TJC, tender joint count; TNF, tumour necrosis factor; TSS, Total Sharp Score; USK, ustekinumab; VAS, Visual Analogue Scale.